PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: PIPELINE ANALYSIS • Pipeline analysis • PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Non-seminoma - Market size and forecast 2018-2023 • Seminoma - Market size and forecast 2018-2023 • Market opportunity by type PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Market trends PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Baxter • Bristol-Myers Squibb • Eli Lilly • Pfizer • Teva Pharmaceutical PART 14: APPENDIX • Research methodology • List of abbreviations PART 15: EXPLORE TECHNAVIO   Exhibit 01: Years in consideration Exhibit 02: Global oncology therapeutics market Exhibit 03: Segments of global oncology therapeutics market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Pipeline drugs in late-stage clinical trials Exhibit 07: Market definition - Inclusions and exclusions checklist Exhibit 08: Market size 2018 Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 10: Global market: Year-over-year growth 2019-2023 (%) Exhibit 11: Five forces analysis 2018 Exhibit 12: Five forces analysis 2023 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2018 Exhibit 19: Type - Market share 2018-2023 (%) Exhibit 20: Comparison by type Exhibit 21: Non-seminoma - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Non-seminoma - Year-over-year growth 2019-2023 (%) Exhibit 23: Seminoma - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Seminoma - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by type Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Asia - Year-over-year growth 2019-2023 (%) Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 36: ROW - Year-over-year growth 2019-2023 (%) Exhibit 37: Key leading countries Exhibit 38: Market opportunity Exhibit 39: Decision framework Exhibit 40: Impact of drivers and challenges Exhibit 41: Vendor landscape Exhibit 42: Landscape disruption Exhibit 43: Vendors covered Exhibit 44: Vendor classification Exhibit 45: Market positioning of vendors Exhibit 46: Baxter - Vendor overview Exhibit 47: Baxter - Business segments Exhibit 48: Baxter - Organizational developments Exhibit 49: Baxter - Geographic focus Exhibit 50: Baxter - Segment focus Exhibit 51: Baxter - Key offerings Exhibit 52: Bristol-Myers Squibb - Vendor overview Exhibit 53: Bristol-Myers Squibb - Business segments Exhibit 54: Bristol-Myers Squibb - Organizational developments Exhibit 55: Bristol-Myers Squibb - Geographic focus Exhibit 56: Bristol-Myers Squibb - Key offerings Exhibit 57: Eli Lilly - Vendor overview Exhibit 58: Eli Lilly - Product segments Exhibit 59: Eli Lilly - Organizational developments Exhibit 60: Eli Lilly - Geographic focus Exhibit 61: Eli Lilly - Segment focus Exhibit 62: Eli Lilly - Key offerings Exhibit 63: Pfizer - Vendor overview Exhibit 64: Pfizer - Business segments Exhibit 65: Pfizer - Organizational developments Exhibit 66: Pfizer - Geographic focus Exhibit 67: Pfizer - Segment focus Exhibit 68: Pfizer - Key offerings Exhibit 69: Teva Pharmaceutical - Vendor overview Exhibit 70: Teva Pharmaceutical - Business segments Exhibit 71: Teva Pharmaceutical - Organizational developments Exhibit 72: Teva Pharmaceutical - Geographic focus Exhibit 73: Teva Pharmaceutical - Segment focus Exhibit 74: Teva Pharmaceutical - Key offerings Exhibit 75: Validation techniques employed for market sizing Exhibit 76: List of abbreviations  

Baxter Bristol-Myers Squibb Eli Lilly Pfizer Teva Pharmaceutical